Literature DB >> 20800244

One single dose of histidine-tryptophan-ketoglutarate solution gives equally good myocardial protection in elective mitral valve surgery as repetitive cold blood cardioplegia: a prospective randomized study.

Bjørn Braathen1, Anders Jeppsson, Henrik Scherstén, Ole M Hagen, Øystein Vengen, Helena Rexius, Vincenzo Lepore, Theis Tønnessen.   

Abstract

OBJECTIVES: Histidine-tryptophan-ketoglutarate (HTK-Custodiol) cardioplegic solution is administered as one single dose for more than 2 hours of ischemia. No prospective randomized clinical study has compared the effects of HTK and cold blood cardioplegia on myocardial damage in elective mitral valve surgery. Thus, the main aim of the present study was to examine whether one single dose of cold antegrade HTK gives as good myocardial protection as repetitive antegrade cold blood cardioplegia in mitral valve surgery.
METHODS: Eighty consecutive patients undergoing elective isolated mitral valve surgery for mitral regurgitation, with or without ablation for atrial fibrillation, were included in the study and randomized to HTK or blood cardioplegia. Markers of myocardial injury (troponin-T and creatine kinase MB) were analyzed at baseline and 7 hours, 1 day, 2 days, and 3 days after surgery.
RESULTS: No significant difference in creatine kinase MB and troponin-T between HTK and blood cardioplegia groups was found at any time point. There was a significant correlation between ischemic time and markers of myocardial injury in the HTK group only and significantly more spontaneous ventricular fibrillation after release of crossclamping in the HTK group.
CONCLUSIONS: One single dose of antegrade cold HTK cardioplegic solution in elective mitral valve surgery protects the myocardium equally well as repetitive antegrade cold blood cardioplegia.
Copyright © 2011 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20800244     DOI: 10.1016/j.jtcvs.2010.07.011

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  17 in total

Review 1.  Is there a rationale for short cardioplegia re-dosing intervals?

Authors:  Yves D Durandy
Journal:  World J Cardiol       Date:  2015-10-26

Review 2.  Custodiol for myocardial protection and preservation: a systematic review.

Authors:  J James B Edelman; Michael Seco; Ben Dunne; Shannon J Matzelle; Michelle Murphy; Pragnesh Joshi; Tristan D Yan; Michael K Wilson; Paul G Bannon; Michael P Vallely; Jurgen Passage
Journal:  Ann Cardiothorac Surg       Date:  2013-11

3.  Myocardial protection during minimally invasive mitral valve surgery: strategies and cardioplegic solutions.

Authors:  Jens Garbade; Piroze Davierwala; Joerg Seeburger; Bettina Pfannmueller; Martin Misfeld; Michael A Borger; Friedrich-Wilhelm Mohr
Journal:  Ann Cardiothorac Surg       Date:  2013-11

4.  Myocardial protection in cardiac surgery: a historical review from the beginning to the current topics.

Authors:  Hiroshi Yamamoto; Fumio Yamamoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-07-23

5.  Custodiol HTK cardioplegia use in robotic mitral valve.

Authors:  Nirav Patel; Ed DeLaney; Gerard Turi; Thomas Stapleton
Journal:  J Extra Corpor Technol       Date:  2013-06

6.  Custodiol Cardioplegia: A Single-Dose Hyperpolarizing Solution.

Authors:  Claus J Preusse
Journal:  J Extra Corpor Technol       Date:  2016-06

7.  Clinical comparative analysis of histidine-tryptophan-ketoglutarate solution and St. Thomas crystalloid cardioplegia: A 12-year study from a single institution.

Authors:  Ying-Zhong Lin; Jing-Bin Huang; Xiang-Wei Li; Xian-Ming Tang; Wei-Jun Lu; Zhao-Ke Wen; Jian Liang; Dian-Yuan Li; Hao Wang
Journal:  Exp Ther Med       Date:  2017-07-19       Impact factor: 2.447

8.  Comparison of the different cardioplegic strategies in cardiac valves surgery: who wins the "arm-wrestling"?

Authors:  Giuseppe Comentale; Raffaele Giordano; Gaetano Palma
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

9.  Different strategies of myocardial protection: the age of perfectionism.

Authors:  Emanuela Angeli; Sabrina Lueck; Gaetano Domenico Gargiulo
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

10.  Acute hemodynamic effects of angiotensin- converting enzyme inhibition after prolonged cardiac arrest with Bretschneider's solution.

Authors:  Alexandro Hoyer; Jörg Kempfert; Patrick Pritzwald-Stegmann; Friedrich-Wilhelm Mohr; Stefan Dhein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-10-12       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.